Grainne O'Kane· @graokane · X·· 2 天前评分70
正文 · 原文
OPTIMUM rand ph2 adv #BTC
➡️dx control on plat- olaparib v olaparib/durva
➡️somatic/ germline DDR but wide range genes
➡️❗️BRCA1/2/PALB2 ~30% (⬆️Olap arm)
❎no diff 6mth PFS
❎1yr OS rate 64 v76%
❗️we must define true HRD in trials & understand TME
@myESMO #ESMO26 @OncoAlert
60 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA37按 Proffered paper: Gynaecological cancers 对上
Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：Grainne O'Kane · x.com